Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302, its experimental immune-modulating therapy being developed for amyotrophic lateral sclerosis (ALS). The funding was secured through the sale of more than 2.5 million company shares to two investors, the company…